|
2024
|
P/S
|
Pharmaceutical preparations for the treatment of central nervous system diseases, namely, neurode... |
|
|
Invention
|
Methods for the treatment of abnormal involuntary movement disorders.
Disclosed herein are new d... |
|
|
Invention
|
Benzoquinoline inhibitors of vesicular monoamine transporter 2.
The present invention relates to... |
|
|
Invention
|
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof.
Provided herein are... |
|
|
Invention
|
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine ... |
|
2023
|
Invention
|
Methods for the treatment of dyskinesia in cerebral palsy.
The disclosure is directed to methods... |
|
|
Invention
|
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof. e.g.,e.g., hyperkine... |
|
|
Invention
|
Pharmaceutical formulations.
The present invention relates to new extended release pharmaceutica... |
|
2022
|
Invention
|
Multiparticulate dosage forms comprising deutetrabenazine.
Provided herein are modified release ... |
|
|
Invention
|
Multiparticulate dosage forms comprising deutetrabenazine. Provided herein are modified release m... |
|
|
Invention
|
Methods of manufacturing benzoquinoline compounds. The present invention relates to new methods o... |
|
|
P/S
|
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutic... |
|
2021
|
Invention
|
Analogs of deutetrabenazine, their preparation and use.
The disclosure is directed to deutetrabe... |
|
|
Invention
|
Gastro retentive dosage forms comprising deutetrabenazine.
Provided herein are controlled releas... |
|
|
Invention
|
Gastro retentive dosage forms comprising deutetrabenazine. e.g.,e.g., hyperkinetic movement disor... |
|
|
Invention
|
Multiparticulate dosage forms comprising deutetrabenazine.
Provided herein are controlled releas... |
|
|
Invention
|
Multiparticulate dosage forms comprising deutetrabenazine. Provided herein are controlled release... |
|
|
Invention
|
Methods for the treatment of abnormal involuntary movement disorders. Disclosed herein are new do... |
|
|
Invention
|
Dihydroxyphenyl neurotransmitter compounds, compositions and methods.
The present invention rela... |
|
|
Invention
|
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof. e.g.e.g., hyperkinet... |
|
|
Invention
|
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof. Provided herein are ... |
|
|
Invention
|
Benzoquinolone inhibitors of vmat2.
The present invention relates to new benzoquinolone inhibito... |
|
|
Invention
|
Novel pharmaceutical formulations.
The present invention relates to new extended release pharmac... |
|
2020
|
Invention
|
Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds.
Described are deuterium... |
|
|
Invention
|
Methods of manufacturing benzoquinoline compounds.
The present invention relates to new methods ... |
|
2019
|
Invention
|
Deutetrabenazine for the treatment of dyskinesia in cerebral palsy. The disclosure is directed to... |
|
|
Invention
|
Methods for the treatment of dyskinesia in cerebral palsy. The disclosure is directed to methods ... |
|
|
P/S
|
Providing medical information relating to neurological diseases |
|
|
Invention
|
Analogs of deutetrabenazine, their preparation and use. The disclosure is directed to deutetraben... |
|
|
Invention
|
Pharmaceutical formulations. The present invention relates to new extended release pharmaceutical... |
|
2018
|
Invention
|
Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator. The p... |
|
2015
|
P/S
|
Pharmaceutical preparations for the treatment of the diseases, disorders and infections of the ce... |
